Stemgen

Stemgen®

Ancestim Hematology An early growth factor with orphan drug status used with Neupogen®–filgrastim–rG-CSF to manage CA Pts receiving stem cell transplants, augmenting the effects of other growth factors to mobilize stem cells into blood for collection and transplantation. See Filgrastim.
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.
References in periodicals archive ?
In September 2008, Amgen sold off rights to its drugs Kepivance and Stemgen to Biovitrum, which also bought an exclusive worldwide license to Kineret for its approved indication.
Swedish pharmaceutical company Biovitrum AB (OMX Stockholm: BVT) announced on Monday (15 September) that it has agreed to acquire the products Kepivance (palifermin) and Stemgen (ancestim) from Amgen (NASDAQ: AMGN).
Amgen, Inc., Thousand Oaks, CA, announced the Biological Response Modifiers Advisory Committee (BRMAC) to the Food and Drug Administration (FDA) has recommended approval of Stemgen, an early-acting blood cell growth factor discovered by Amgen's scientists for use in the treatment of cancer patients receiving stem cell transplants.